Free tool
FAERS Monitor: Lumryz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214755 or its brand name (Lumryz, Sodium Oxybate). Reports on generic versions are filed under their own applications.
Reports
5,012
Serious
1,731
35% of reports
Hospitalization
512
Death reported
123
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- somnolence896
- insomnia872
- middle insomnia807
- nausea748
- product dose omission issue645
- fatigue612
- drug ineffective567
- initial insomnia454
- dizziness405
- anxiety401
- intentional dose omission384
- feeling abnormal377
- nocturia369
- vomiting363
- headache340
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 27 |
| 2011 | 15 |
| 2012 | 12 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 17 |
| 2016 | 16 |
| 2017 | 22 |
| 2018 | 52 |
| 2019 | 39 |
| 2020 | 19 |
| 2021 | 28 |
| 2022 | 28 |
| 2023 | 551 |
| 2024 | 2,469 |
| 2025 | 1,233 |
| 2026 | 467 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,147 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| initial insomniaSignal | 454 | 194.2 | 177.5 | 83,270 |
| middle insomniaSignal | 807 | 189.5 | 177.6 | 144,747 |
| nocturiaSignal | 369 | 131.5 | 119.0 | 46,229 |
| intentional dose omissionSignal | 384 | 57.3 | 52.0 | 20,921 |
| somnolenceSignal | 896 | 18.8 | 17.7 | 15,118 |
| insomniaSignal | 872 | 13.8 | 13.0 | 10,422 |
| product dose omission issueSignal | 645 | 9.2 | 8.6 | 4,777 |
| feeling abnormalSignal | 377 | 6.6 | 6.0 | 1,807 |
| anxietySignal | 401 | 5.9 | 5.4 | 1,655 |
| nauseaSignal | 748 | 4.0 | 3.7 | 1,721 |
| dizzinessSignal | 405 | 3.4 | 3.1 | 703 |
| fatigueSignal | 612 | 3.3 | 3.1 | 1,016 |
| vomitingSignal | 363 | 3.2 | 2.9 | 573 |
| headacheSignal | 340 | 2.3 | 2.1 | 249 |
| drug ineffective | 567 | 1.8 | 1.7 | 217 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.